SLCH Consortium Hematology and Medical Oncology

Topics

• Acute Myeloid Leukemia Research 377
• Lymphoma Diagnosis and Treatment 349
• Multiple Myeloma Research and Treatments 303
• Hematopoietic Stem Cell Transplantation 264
• CAR-T cell therapy research 225
• Lung Cancer Treatments and Mutations 178
• Immune Cell Function and Interaction 163
• Venous Thromboembolism Diagnosis and Management 159
• T-cell and Retrovirus Studies 135
• Chronic Lymphocytic Leukemia Research 111
• HIV Research and Treatment 104
• Myeloproliferative Neoplasms: Diagnosis and Treatment 101

Most cited

1. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

   The New England journal of medicine · 2022 · 1,350 citations · Armin Ghobadi, Peter Riedell

2. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

   Lancet (London, England) · 2024 · 686 citations · George Ansstas

3. Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

   The New England journal of medicine · 2021 · 1,513 citations · Ramaswamy Govindan

4. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

   The New England journal of medicine · 2021 · 1,483 citations · James Hsieh

5. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

   The New England journal of medicine · 2022 · 793 citations · Neha Mehta-Shah

6. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

   The New England journal of medicine · 2023 · 653 citations · Ravi Vij